Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia

Exclusion Criteria

• •Previous intolerance leading to discontinuation of polymer-based phosphate binder therapy
• •History of noncompliance with phosphate binder therapy in the opinion of the investigator
• •Anticipating or scheduled for a living related-donor kidney transplant, or a prior recipient of a kidney transplant
• •Current use of antiarrhythmic or anti-seizure medication
• •Active ethanol or drug dependence or abuse, excluding tobacco use
• •A screening serum calcium (corrected for albumin) \< 8.4 mg/dL
• •History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders, major gastrointestinal surgery, or gastric/duodenal ulcers within 6 months prior to screening
• •Subject is pregnant, breast feeding, or is of child bearing potential and is not using adequate contraceptive precautions
• •Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s)
• •Subject has experienced a myocardial infarction or major surgery (excluding vascular access surgery) within 3 months prior to screening
• •Clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of localized basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia